Details of the Drug

General Information of Drug (ID: DMZEONG)

Drug Name
Finafloxacin
Synonyms
Finafloxacin hydrochloride; Antibacterial (Helicobacter pylori infection/ bacterial urinary tract infection), Combinature; Finafloxacin (iv, bacterial infection), MerLion/Alcon; Finafloxacin (oral, bacterial infection), MerLion/Alcon
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1]
Affected Organisms
Pseudomonas aeruginosaGram-positive BacteriaEnteric bacteria and other eubacteria
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 398.4
Logarithm of the Partition Coefficient (xlogp) -0.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.75 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 13.42 hours [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.75% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.42 L/kg [3]
Chemical Identifiers
Formula
C20H19FN4O4
IUPAC Name
7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
InChI
InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
InChIKey
FYMHQCNFKNMJAV-HOTGVXAUSA-N
Cross-matching ID
PubChem CID
11567473
ChEBI ID
CHEMBL85176
CAS Number
209342-40-5
UNII
D26OSN9Q4R
DrugBank ID
DB09047
TTD ID
D01IXD
ACDINA ID
D01077
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Modulator [1]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium chloride E00077 5234 Diluent; Tonicity agent
Water E00035 962 Solvent
Magnesium chloride E00479 5360315 Viscosity-controlling agent
Hydroxyethyl cellulose E00700 Not Available Coating agent; Suspending agent; Binding agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Finafloxacin 0.3% suspension 0.30% Suspension Otic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds